MiniMed Group, Inc. Common Stock (MMED) Fair Value & Analysis
Healthcare · US · Market cap $4.3B · ISIN US60365F1093
MiniMed Group, Inc. Common Stock
MMED · US
Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Risks
Fair value as of: Aug 13, 2026
From 6 valuation models · updated 16 days ago
Fair value updated Aug 13, 2026, revised from $3.69 to $3.51 (−4.9%) since Jul 16, 2026. Share price +9.2% over the past month.
Below-average quality, and trading another 473% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($4.25). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (6 months)
White line = price, green steps = our fair value per fiscal year. As of Aug 13, 2026.
How to read this chart
6‑month range $10.80 – $20.70 · fair‑value band $2.77 – $4.25 · the $20.10 price screens above the $3.51 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Aug 13, 2026.
Analysis
MiniMed Group, Inc. Common Stock (MMED) currently trades at $20.10, while our model-based Fair Value estimate is $3.51, implying the stock looks roughly 82.5% overvalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, MiniMed Group, Inc. Common Stock generated revenue of $3.0B at a net margin of -10.7%. Revenue grew 15.0% year over year. The balance sheet holds a net cash position of $153M. Fundamentals as of Aug 13, 2026
Our scenario range runs from $2.77 (bear case) to $4.25 (bull case); at $20.10, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 2% below its 52-week high and 89% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at -83%, MMED screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: Asset-Based ($8.61) versus Earnings-Based ($1.98). Highest evidence: ROIC Compounder (67).
Notify me when MMED reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 62
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services.
Full company description
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera, or Guardian 4, and wraparound applications and services. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2023 – FY2026 · reported fiscal years
MiniMed Group, Inc. Common Stock reported revenue of $3.1B in FY2026 versus $2.2B in FY2023, a compound +11.4%/yr. Reported net income was −$331M in FY2026.
MMED screens 83% overvalued. Compare with Intuitive Surgical, Inc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Can Abbott Laboratories (ABT)’s Instinct Sensor Give MiniMed Group (MMED) a Competitive Edge?
- MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor
- MiniMed's Smallest App-Controlled Insulin Pump Now Shipping with the World's Smallest Sensor
Peer Group
Medical Instruments & Supplies · 205 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $367.07 | $150.04 | -59% |
| EssilorLuxottica Société anonyme EL | €157.50 | €94.93 | -40% |
| Medline Inc MDLN | $34.58 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $190.21 | $100.46 | -47% |
| Alcon Inc ALC | $72.23 | $39.78 | -45% |
| ResMed Inc RMD | A$32.39 | A$26.05 | -20% |
| West Pharmaceutical Services, Inc WST | $337.47 | $141.58 | -58% |
| Sartorius Stedim Biotech S.A DIM | €196.70 | €48.88 | -75% |
| Straumann Holding STMN | CHF 92.18 | CHF 47.31 | -49% |
| Sartorius Aktiengesellschaft SRT3 | €253.50 | €63.30 | -75% |
Compare MiniMed Group, Inc. Common Stock with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is MiniMed Group, Inc. Common Stock (MMED) overvalued or undervalued?
What is the fair value of MMED?
What is the quality score of MMED?
What is the revenue of MiniMed Group, Inc. Common Stock (MMED)?
What is the net profit margin of MMED?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch MiniMed Group, Inc. Common Stock in the live analysis
One click puts MiniMed Group, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.